asxl1

ASXL1 (additional sex combs like 1)

ASXL1 is a ~165 kDa nuclear chromatin regulator and non-catalytic scaffold of the polycomb repressive deubiquitinase (PR-DUB) complex. It is the third most commonly mutated gene in clonal hematopoiesis of indeterminate potential (CHIP) after dnmt3a and tet2, and is frequently truncated in myeloid malignancies. Somatic ASXL1 mutations accumulate in aging hematopoietic stem cells and are associated with systemic inflammation, cardiovascular risk, and impaired hematopoiesis.

Identity

• UniProt: Q8IXJ9 (ASXL1_HUMAN) — manually reviewed (Swiss-Prot)
• NCBI Gene: 171023
• HGNC symbol: ASXL1
• Ensembl: ENSG00000171456
• Protein length: 1,541 amino acids (canonical isoform)
• Molecular weight: ~165 kDa
• Subcellular location: Nucleus

Key functional domains

• HTH HARE-type domain (residues 11–86) — chromatin reader module; binds modified histone tails
• DEUBAD domain (residues 255–364) — required for BAP1 activation within the PR-DUB complex; mutations in this region abolish deubiquitinase stimulation
• PHD-type zinc finger (residues 1503–1540, C-terminal) — likely histone-binding; most CHIP frameshift mutations produce truncations that eliminate this domain
• LXXLL motif — mediates interaction with nuclear receptors RARA and RXRA via NCOA1

Function

ASXL1 serves as the non-catalytic scaffold of the PR-DUB complex, whose catalytic core is the bap1 deubiquitinase (BAP1/BRCA1-associated protein 1) ¹. The complex mediates deubiquitination of histone H2A at lysine 119 (H2AK119ub1), a mark placed by PRC1. By opposing H2AK119 ubiquitination, PR-DUB activity counterbalances Polycomb silencing at developmental and lineage-commitment gene loci.

Additional functions:

• Indirectly regulates H3K27me3 levels — loss of ASXL1 leads to global H3K27me3 reduction, dysregulating Hox gene expression and other developmental loci ²
• Coactivates retinoic acid receptors RARA/RXRA via NCOA1
• Interacts with FOXK1/K2, MBD5/MBD6, KDM1B, and HCFC1 within extended PR-DUB complex assemblies

CHIP biology

ASXL1 is among the most common drivers of CHIP, identified in the landmark 2014 NEJM studies that established the CHIP concept in large human cohorts ³⁴. Rank ordering varies by cohort and detection method: in Jaiswal 2014 (n=17,182), ASXL1 is third after DNMT3A and TET2; in Genovese 2014 (n=12,380), ASXL1 (35 mutations) appeared second — ahead of TET2 (31), likely due to TET2 under-detection from exon-capture gaps noted by the authors. Across the literature, ASXL1 is consistently cited as the third most common CHIP driver. CHIP prevalence increases steeply with age; ASXL1-mutant clones are detected in ~0.3–1% of individuals over 60 (estimates vary by variant-allele-fraction threshold).

Mutation pattern — paradoxical gain-of-function truncation

Nearly all ASXL1 CHIP mutations are frameshift or nonsense variants in exon 12, producing C-terminal truncations that delete the PHD zinc finger ⁵. Despite superficial resemblance to loss-of-function mutations, these truncations appear to gain function — the truncated protein retains the DEUBAD domain and scaffold capacity but loses normal regulation, causing paradoxical hyperactivation or misdirection of the PR-DUB complex. This distinguishes ASXL1 from classic tumor suppressors and complicates therapeutic targeting. no-mechanism — the precise molecular gain-of-function mechanism of C-terminal truncating ASXL1 mutations remains incompletely defined.

Inflammatory phenotype

ASXL1-CHIP is associated with elevated circulating CRP and IL-6, indicating a distinct inflammatory signature ⁵. This contrasts with dnmt3a- and tet2-CHIP, where the IL-6/IL-1beta-driven NLRP3 inflammasome mechanism is better characterized. Whether the ASXL1-CHIP inflammatory signal operates through the same myeloid-lineage-expansion pathway or via distinct epigenetic dysregulation of inflammatory gene programs is not fully resolved. no-mechanism

Clonal expansion kinetics

ASXL1-mutant clones tend to expand more aggressively than DNMT3A or TET2 clones, and are enriched at higher variant-allele fractions in population surveys. This correlates with the higher rate of ASXL1 mutations in overt myeloid malignancies relative to its CHIP prevalence ⁵.

Role in hematopoietic stem cells

Hematopoietic-specific conditional deletion of Asxl1 in mice (Asxl1-fl/fl; Vav-Cre or Mx1-Cre) produces:

• Myelodysplastic syndrome (MDS) features: multilineage cytopenias, dysplastic morphology
• Expanded Lin-Sca1+cKit+ (LSK) stem/progenitor compartment with impaired functional self-renewal (competitive transplantation disadvantage; self-renewal defect worsened in serial transplantation)
• Dysregulated Hox gene expression (HoxA7, HoxA9 up-regulated); age-dependent increase in p16INK4a in LT-HSCs consistent with global H3K27me3 reduction
• Combined Asxl1/Tet2 double-KO (Mx1-Cre system) rescues the self-renewal defect caused by Asxl1 loss alone — Tet2 co-deletion restores serial-replating capacity and confers a competitive advantage in transplantation, while still producing an accelerated MDS-like myeloid disorder (not AML) ²

This mouse phenotype models the human ASXL1-mutant hematopoietic dysfunction, though full germline Asxl1 deletion causes severe developmental defects inconsistent with normal viability (anophthalmia, cleft palate), indicating the gene’s role extends beyond hematopoiesis.

Dimension	Status	Notes
Pathway conserved in humans?	yes	PR-DUB complex is conserved; BAP1 is H. sapiens ortholog
Phenotype conserved in humans?	yes	ASXL1-mutant MDS/AML and CHIP occur in humans
Replicated in humans?	yes	CHIP studies in humans; mouse KO models mechanistic detail

Disease associations

Disease	Context
Myelodysplastic syndrome (MDS)	One of most frequently mutated genes; poor prognosis
Myeloproliferative neoplasms (MPN)	Present in ~5–10% of cases
Chronic myelomonocytic leukemia (CMML)	Mutated in ~40–50% of cases; among highest frequencies
Acute myeloid leukemia (AML)	Secondary AML from antecedent CHIP/MDS
Bohring-Opitz syndrome	Germline de novo nonsense mutations; severe developmental syndrome 6
CHIP	Somatic; age-related clonal expansion with CVD/mortality risk

Aging relevance

ASXL1-CHIP contributes to the aging phenotype through at least two mechanisms:

1. Systemic inflammation — mutant myeloid progeny secrete elevated inflammatory cytokines, contributing to inflammaging and chronic-inflammation
2. Impaired hematopoiesis — clonal dominance of functionally inferior ASXL1-mutant HSCs progressively displaces wild-type HSCs, contributing to stem-cell-exhaustion and the myeloid-skewing characteristic of aging hematopoiesis

The same all-cause mortality and cardiovascular risk signal documented for DNMT3A- and TET2-CHIP ⁴ applies broadly to ASXL1-CHIP ⁷, though ASXL1-specific hazard ratios and cardiovascular mechanisms are less well-characterized than for TET2. needs-replication

Therapeutic landscape

No direct ASXL1-targeting therapy exists. The gain-of-function nature of truncating mutations makes standard LOF-correction strategies (e.g., reconstituting expression) inappropriate. Current and investigational approaches:

• CHIP-stratified cardiovascular trials — CANTOS (canakinumab anti-IL-1beta) showed benefit in TET2-CHIP specifically; ASXL1-CHIP subgroup analyses have not demonstrated a statistically independent signal, likely due to smaller subgroup sizes needs-replication
• BAP1 inhibition — theoretical target (ASXL1 truncations hyperactivate BAP1); no clinical compound advanced
• HSC competition strategies — gene-corrected HSC transplantation to outcompete mutant clones (preclinical concept only)

needs-canonical-id — druggability-tier not populated; no Open Targets Platform entry confirmed for ASXL1 as a direct drug target. Recommend lookup at api.platform.opentargets.org on next update cycle.

Pathway and process membership

ASXL1 is not a signaling pathway component in the conventional sense; it functions as a chromatin-level epigenetic regulator influencing transcription at developmental and hematopoietic loci. Its loss/truncation dysregulates:

• H2AK119 deubiquitination (PR-DUB)
• H3K27me3 distribution (indirect; opposes PRC2 activity)
• Hox gene expression programs
• Inflammatory gene programs in myeloid cells

Key interactors

• bap1 — catalytic partner in PR-DUB; ASXL1 DEUBAD domain activates BAP1 deubiquitinase activity; no dedicated wiki page yet
• dnmt3a — sibling CHIP driver; operates via independent DNA methylation mechanism
• tet2 — sibling CHIP driver; operates via 5mC hydroxymethylation; synergizes with ASXL1 loss in mouse models
• FOXK1/K2, MBD5, MBD6, KDM1B, HCFC1 — extended PR-DUB complex members (no wiki pages)

Cross-references

• clonal-hematopoiesis — master page for CHIP biology
• hematopoietic-stem-cells — HSC biology and aging context
• dnmt3a — most common CHIP driver
• tet2 — second most common CHIP driver
• epigenetic-alterations — hallmark context
• inflammaging — downstream phenotype of CHIP-driven inflammation

Limitations and gaps

• gtex-aging-correlation: not populated — ASXL1 is expressed across tissues but GTEx aging correlation for this gene has not been systematically extracted for this wiki. unsourced
• mr-causal-evidence: not-applicable-somatic — CHIP is driven by somatic (acquired) mutations, not inherited germline variants; germline MR studies are structurally inapplicable for CHIP-driver genes.
• ASXL1-CHIP differential cardiovascular mechanism (vs TET2) is poorly characterized. no-mechanism
• The gain-of-function mechanism of C-terminal truncations remains unresolved at the structural level. no-mechanism
• No clinical trials specifically targeting ASXL1-CHIP identified (as distinct from general CHIP or TET2-CHIP trials). needs-replication

Footnotes

Footnotes

1. UniProt Q8IXJ9 (ASXL1_HUMAN), accessed 2026-05-06 · manually curated Swiss-Prot entry · functional annotation with cited evidence ↩

2. doi:10.1084/jem.20131141 · Abdel-Wahab et al. · J Exp Med 2013 · in-vivo (mouse, conditional Asxl1 KO; Vav-Cre primary phenotype; Mx1-Cre for double-KO survival studies) · demonstrated MDS-like phenotype with expanded LSK compartment, impaired self-renewal, dysregulated Hox gene expression, and age-dependent cytopenias; concurrent Tet2 deletion (double-KO) rescues the self-renewal defect but produces an accelerated myelodysplastic disorder — Tet2 co-deletion does not accelerate to AML; local PDF available ↩ ↩²

3. doi:10.1056/NEJMoa1409405 · Genovese et al. · NEJM 2014 · n=12,380 exome sequences · observational · model: human population cohort (Swedish national registers) · identified clonal hematopoiesis mutations including ASXL1 in 10% of individuals over 65; associated with HR 12.9 (95% CI 5.8–28.7) for subsequent hematologic cancer and HR 1.4 (95% CI 1.0–1.8) for death; ASXL1 had 35 mutations (second most common driver in this cohort after DNMT3A, ahead of TET2’s 31); local PDF available ↩

4. doi:10.1056/NEJMoa1408617 · Jaiswal et al. · NEJM 2014 · n=17,182 whole-exome sequences · observational · model: 22 population-based cohorts across 3 consortia (median age 58 yr) · CHIP associated with HR 1.4 (95% CI 1.1–1.8) for all-cause mortality; HR 11.1 (95% CI 3.9–32.6) for hematologic cancer; HR 2.0 (95% CI 1.2–3.5) for incident coronary heart disease; HR 2.6 (95% CI 1.3–4.8) for ischemic stroke; ASXL1 had 62 variants — third most common driver in this cohort (DNMT3A=403, TET2=72, ASXL1=62); local PDF available ↩ ↩²

5. doi:10.1016/j.exphem.2020.01.002 · Fujino et al. · Exp Hematol 2020 · review · examines ASXL1 CHIP mutation spectrum, clonal expansion, and the gain-of-function paradox of C-terminal truncating mutations ↩ ↩² ↩³

6. doi:10.1038/ng.868 · Hoischen et al. · Nat Genet 2011 · n=8 trios + replication cohort · observational (de novo mutation mapping) · model: human genetic syndrome · identified de novo nonsense mutations in ASXL1 as the cause of Bohring-Opitz syndrome ↩

7. doi:10.1016/j.jacc.2023.03.401 · Gumuser et al. (incl. Natarajan) · JACC 2023 · n=13,129 individuals with established atherosclerotic CVD (5.1% had CHIP) · observational (cohort) · CHIP associated with adjusted HR 1.23 for composite ASCVD events and all-cause mortality over median 10.8 yr follow-up; TET2 and spliceosome mutations showed strongest signals; large ASXL1 CHIP (VAF ≥10%) associated with adjusted HR ~1.44 for primary composite outcome; PDF download failed — verified via PMC abstract PMC10249057 no-fulltext-access ↩